Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

Similar articles for PubMed (Select 21351746)

1.

Aminothiazolomorphinans with mixed κ and μ opioid activity.

Zhang T, Yan Z, Sromek A, Knapp BI, Scrimale T, Bidlack JM, Neumeyer JL.

J Med Chem. 2011 Mar 24;54(6):1903-13. doi: 10.1021/jm101542c. Epub 2011 Feb 25.

2.

Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.

Provencher BA, Sromek AW, Li W, Russell S, Chartoff E, Knapp BI, Bidlack JM, Neumeyer JL.

J Med Chem. 2013 Nov 14;56(21):8872-8. doi: 10.1021/jm401290y. Epub 2013 Oct 29.

3.

2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.

Zhang A, Xiong W, Hilbert JE, DeVita EK, Bidlack JM, Neumeyer JL.

J Med Chem. 2004 Apr 8;47(8):1886-8.

PMID:
15055988
4.

Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.

Neumeyer JL, Zhang A, Xiong W, Gu XH, Hilbert JE, Knapp BI, Negus SS, Mello NK, Bidlack JM.

J Med Chem. 2003 Nov 20;46(24):5162-70.

PMID:
14613319
5.

Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.

Zhang B, Zhang T, Sromek AW, Scrimale T, Bidlack JM, Neumeyer JL.

Bioorg Med Chem. 2011 May 1;19(9):2808-16. doi: 10.1016/j.bmc.2011.03.052. Epub 2011 Mar 26.

6.

Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.

Neumeyer JL, Gu XH, van Vliet LA, DeNunzio NJ, Rusovici DE, Cohen DJ, Negus SS, Mello NK, Bidlack JM.

Bioorg Med Chem Lett. 2001 Oct 22;11(20):2735-40.

PMID:
11591513
8.

High-affinity carbamate analogues of morphinan at opioid receptors.

Peng X, Knapp BI, Bidlack JM, Neumeyer JL.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.

9.
10.

Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan.

Srivastava SK, Shefali S, Miller CN, Aceto MD, Traynor JR, Lewis JW, Husbands SM.

J Med Chem. 2004 Dec 16;47(26):6645-8.

PMID:
15588100
11.

Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.

Mathews JL, Peng X, Xiong W, Zhang A, Negus SS, Neumeyer JL, Bidlack JM.

J Pharmacol Exp Ther. 2005 Nov;315(2):821-7. Epub 2005 Aug 2.

12.

Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.

Neumeyer JL, Bidlack JM, Zong R, Bakthavachalam V, Gao P, Cohen DJ, Negus SS, Mello NK.

J Med Chem. 2000 Jan 13;43(1):114-22.

PMID:
10633042
13.
14.

Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.

Spetea M, Schüllner F, Moisa RC, Berzetei-Gurske IP, Schraml B, Dörfler C, Aceto MD, Harris LS, Coop A, Schmidhammer H.

J Med Chem. 2004 Jun 3;47(12):3242-7.

PMID:
15163203
15.

Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.

Ananthan S, Johnson CA, Carter RL, Clayton SD, Rice KC, Xu H, Davis P, Porreca F, Rothman RB.

J Med Chem. 1998 Jul 16;41(15):2872-81.

PMID:
9667975
16.

Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.

Li G, Aschenbach LC, Chen J, Cassidy MP, Stevens DL, Gabra BH, Selley DE, Dewey WL, Westkaemper RB, Zhang Y.

J Med Chem. 2009 Mar 12;52(5):1416-27. doi: 10.1021/jm801272c.

17.

Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.

Greiner E, Spetea M, Krassnig R, Schüllner F, Aceto M, Harris LS, Traynor JR, Woods JH, Coop A, Schmidhammer H.

J Med Chem. 2003 Apr 24;46(9):1758-63.

PMID:
12699394
18.

Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.

Wang YJ, Tao YM, Li FY, Wang YH, Xu XJ, Chen J, Cao YL, Chi ZQ, Neumeyer JL, Zhang A, Liu JG.

J Pharmacol Exp Ther. 2009 Apr;329(1):306-13. doi: 10.1124/jpet.108.142802. Epub 2009 Jan 9.

19.

Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists.

Cheng K, Kim IJ, Lee MJ, Adah SA, Raymond TJ, Bilsky EJ, Aceto MD, May EL, Harris LS, Coop A, Dersch CM, Rothman RB, Jacobson AE, Rice KC.

Org Biomol Chem. 2007 Apr 21;5(8):1177-90. Epub 2007 Mar 1.

PMID:
17406716
20.

Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.

McLamore S, Ullrich T, Rothman RB, Xu H, Dersch C, Coop A, Davis P, Porreca F, Jacobson AE, Rice KC.

J Med Chem. 2001 Apr 26;44(9):1471-4.

PMID:
11311071
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk